• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

    11/8/24 10:52:38 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2 )*

                

    ZAI LAB LTD. - SB


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G9887T116


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G9887T116

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 107,963,206
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 118,191,071
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    118,191,071
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    11.87%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. G9887T116

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 107,963,206
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 118,191,071
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    118,191,071
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    11.87%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. G9887T116

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 107,963,206
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 118,191,071
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    118,191,071
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    11.87%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. G9887T116

    1. NAMES OF REPORTING PERSONS

    Wellington Management Company LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 103,742,573
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 107,365,651
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    107,365,651
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    10.78%
    12. TYPE OF REPORTING PERSON

    IA

    Item 1.
    (a) Name of Issuer
    ZAI LAB LTD. - SB
    (b) Address of Issuer's Principal Executive Offices
    4560 Jinke Road, Building 1
    4th Floor, Jinchuang Plaza
    Pudong, Shanghai F4 201210
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    Wellington Management Company LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    Wellington Management Company LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G9887T116
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); *
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Wellington Management Group LLP - HC
    Wellington Group Holdings LLP - HC
    Wellington Investment Advisors Holdings LLP - HC
    Wellington Management Company LLP - IA
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Item 7 directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:


    Vanguard Health Care Fund
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    By: Wellington Management Company LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: November 14,2024

    Get the next $ZLAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    11/11/2021$222.00 → $217.00Buy
    Citigroup
    More analyst ratings

    $ZLAB
    SEC Filings

    See more
    • SEC Form 144 filed by Zai Lab Limited

      144 - Zai Lab Ltd (0001704292) (Subject)

      6/26/25 4:41:52 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Zai Lab Limited

      144 - Zai Lab Ltd (0001704292) (Subject)

      6/26/25 4:29:44 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Zai Lab Limited

      144 - Zai Lab Ltd (0001704292) (Subject)

      6/20/25 9:44:49 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Zai Lab with a new price target

      Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

      3/7/25 8:00:31 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab downgraded by BofA Securities with a new price target

      BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

      3/3/25 7:38:45 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Zai Lab with a new price target

      Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50

      12/14/23 7:54:36 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

      -Data highlights potential of ZL-1503 as a promising treatment for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases -Favorable preclinical safety profile, prolonged half-life and durable suppression of both inflammatory and pruritogenic pathways support advancement of ZL-1503 to IND-enabling studies -Zai Lab plans to file an IND for ZL-1503 for moderate-to-severe atopic dermatitis by the end of 2025 Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced new data from its preclinical study of ZL-1503, the Company's promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-ca

      6/13/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

      6/2/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)

      5/31/25 3:08:00 PM ET
      $NVCR
      $ZLAB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations